Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 1.1 -0.01 (-0.9%) Market Cap: 281.12 Mil Enterprise Value: 163.71 Mil PE Ratio: 0 PB Ratio: 11.00 GF Score: 66/100

Q4 2018 Adaptimmune Therapeutics PLC Earnings Call Transcript

Feb 27, 2019 / 01:00PM GMT
Release Date Price: $4.64 (-4.53%)
Operator

Good day, ladies and gentlemen, and welcome to the Adaptimmune Therapeutics conference call. (Operator Instructions)

I would now like to introduce your host for today's conference, Juli Miller. You may begin.

Juli P. Miller
Adaptimmune Therapeutics plc - Director of IR

Good morning, and welcome to Adaptimmune's conference call to discuss our fourth quarter and full year 2018 financial results and other business updates. We issued a press release earlier this morning, and I would ask you to please review the full text of our forward-looking statements. As a reminder, we anticipate making projections during this call, and actual results could differ materially due to a number of factors.

In addition, I would like to make you aware of an update to our SPEAR T-cell nomenclature. From here forward, we will refer to our SPEAR T-cell's with a prefix, ADP for our company name, followed by a reference to the HLA-type specific for the SPEAR T-cell, which is currently A2 for all of our trials and then a reference to the target antigen.

So

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot